Discontinuation rates, read honestly
An effect is dose-limiting when it prevents adequate intake, prevents normal activity, or produces a risk of its own. Discomfort alone is not the test.
Delphine Ruzek
Page 6 of 7 of this archive, newest first.
Archive — page 6
121 piecesDelayed emptying explains some of this, and not all of it
The clinical effect profile is almost fully predictable from where the receptor is expressed, which is unusual and useful.
Lipohypertrophy, and the absorption it ruins
A rotation scheme that is too complicated will not be followed. We describe the simple ones that are.
The mechanism behind the mechanism
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
Sarcopenia is a diagnosis, not a synonym for losing lean mass
The rule that a quarter of weight lost is lean tissue has been in textbooks for decades and does not survive close reading.
Pancreatitis, obstruction, gallbladder: three things nausea can be
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
The qualification chain nobody in this trade can show you
Accreditation to the international competence standard covers the scope a laboratory has been assessed for, which is not necessarily the test you commissioned.
What the trials adjudicated, and how
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
The eighteenth month, and the conversation that should have happened in the third
Weight reduction in the long programmes flattens at roughly sixty to seventy-two weeks. The timing is consistent, predictable and almost never mentioned in advance.
Reflux, early satiety, and the volume the stomach will accept
A single drug producing both constipation and diarrhoea looks contradictory until the motility data is read properly.
A missed dose, modelled: what happens to retatrutide concentrations over the following fortnight
An accumulation model, drawn from published parameters, with its assumptions stated.
Sarcopenia is a diagnosis, not a synonym for losing lean mass
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
Reflux, early satiety, and the volume the stomach will accept
What scintigraphy and breath-test studies established about emptying rate, and what they did not.
Escalating past the approved maximum, examined honestly
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.
Two sessions a week, and the evidence behind the prescription
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
What the anaesthetists said, and then said again
What endoscopic and ultrasound studies found about residual gastric content, and what the aspiration data does and does not support.
The trade has decided the ceiling is arbitrary. The trials disagree.
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.
The arithmetic of a step: what doubling a dose actually asks of you
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
A needle is a single-use instrument
A needle blunts on first use. Reuse is uncomfortable, and it is a documented contributor to lipohypertrophy.
What STEP 4 and SURMOUNT-4 actually established
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.